What are ANI Pharmaceuticals's total assets?

ANI Pharmaceuticals (ANIP) holds $1.4B in total assets, up 10.0% year over year.

How much debt does ANI Pharmaceuticals have?

ANI Pharmaceuticals carries $305.3M in total debt against $562.3M of shareholders' equity, a debt-to-equity ratio of 0.54.

How much cash does ANI Pharmaceuticals have?

ANI Pharmaceuticals holds $311.2M in cash and equivalents.

Can ANI Pharmaceuticals cover its short-term obligations?

Its current ratio is 3.12 — current assets exceed current liabilities.

Where does ANI Pharmaceuticals's balance sheet data come from?

Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

ANI Pharmaceuticals ANIP Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$311.21M+108%	$285.62M+97.1%	$262.65M+81.1%	$217.83M-9.3%	$149.84M-34.5%
Restricted cash	$36K—	$36K—	$36K—	$36K—	——
Accounts receivable, net	$255.43M+15.9%	$281.08M+26.8%	$252.62M+28.6%	$225.65M+35.9%	$220.33M+27.8%
Inventories	$143.47M+4.4%	$143.07M+4.6%	$146.48M-1.1%	$138.32M+10.3%	$137.41M+20.7%
Raw materials	$83.33M+37.0%	$84.11M+25.2%	$68.65M+2.1%	$63.85M+2.0%	$60.83M+10.4%
Work in process	$5.29M-3.5%	$2.97M+78.6%	$5M+20.7%	$4.9M+2.6%	$5.48M+81.7%
Finished goods	$54.85M-8.6%	$55.99M-3.4%	$63.12M-4.6%	$59.64M+25.1%	$59.98M+30.8%
Prepaid expenses and other current assets	$22.09M-5.3%	$34.22M+90.4%	$18.55M+6.2%	$15.11M+7.9%	$23.33M+45.3%
Derivative assets	$1.51M-58.1%	$1.65M-66.4%	$2.23M-37.2%	$2.81M-61.8%	$3.61M-52.8%
Total current assets	$747.08M+39.3%	$753.12M+42.5%	$698.4M+34.0%	$602.63M+8.5%	$536.29M-0.8%
Property and equipment, net	$67.12M+15.4%	$62.48M+9.9%	$63.56M+12.1%	$59.25M+14.7%	$58.18M+19.9%
Accumulated depreciation	$469.01M+20.7%	$450.35M+22.4%	$429.97M+23.8%	$409.57M+22.8%	$388.5M+21.2%
Goodwill	$62.48M+3.0%	$62.48M+4.2%	$62.48M+3.4%	$60.53M+114%	$60.66M+115%
Intangible assets, net	$467.16M-10.6%	$479.53M-11.5%	$499.82M-9.1%	$520.32M+219%	$522.7M+197%
Deferred tax assets	$66.56M-24.8%	$69.07M-18.8%	$71.4M+5.5%	$92.03M+2.8%	$88.49M+1.0%
Other non-current assets	$11.58M+12.2%	$13.71M+12.2%	$12.5M+9.0%	$8.25M-35.8%	$10.31M-24.0%
Equity securities	$14.89M+176%	$9.13M+44.8%	$8.86M+6.8%	$5.72M—	$5.39M—
Total assets	$1.42B+10.0%	$1.44B+12.1%	$1.41B+9.4%	$1.34B+45.9%	$1.29B+41.3%
Accounts payable	$69.69M+31.4%	$62.58M+37.1%	$69.8M+14.6%	$54.57M+12.1%	$53.06M+7.3%
Accrued expenses	$16.09M-27.8%	$37.9M+0.5%	$33.22M+11.6%	$32.93M+104%	$22.3M+134%
Current portion of long-term debt	$19.3M+72.4%	$17.27M+88.3%	$15.24M+113%	$13.22M+1,455%	$11.19M+1,217%
Finance Lease Liability, Current	——	——	——	——	——
Income taxes payable	$5.3M-62.7%	$2.24M-60.2%	$0—	$3.29M—	$14.19M—
Total current liabilities	$239.51M+18.7%	$278.11M+43.0%	$270.56M+42.4%	$236.84M+69.2%	$201.82M+47.4%
Long-term debt	$286M-6.3%	$291.84M-5.6%	$297.68M-4.9%	$301.48M+6.0%	$305.29M+7.3%
Finance Lease Liabilities (Total)	——	——	——	——	——
Finance lease liabilities	——	——	——	——	——
Other non-current liabilities	$16.45M+134%	$12.16M+110%	$11.27M+62.3%	$6.7M+43.1%	$7.02M+38.9%
Total liabilities	$859.67M+1.3%	$899.65M+5.1%	$902.34M+5.3%	$881.39M+100%	$848.96M+94.0%
Preferred stock	$0—	$0—	$0—	$0—	$0—
Common stock	$3K+50.0%	$3K+50.0%	$3K+50.0%	$2K0.0%	$2K0.0%
Additional paid-in capital	$608.43M+14.6%	$596.04M+14.7%	$586.23M+14.7%	$541.9M+1.8%	$531.06M+1.4%
Retained earnings	$6.39M+108%	-$23.1M+77.0%	-$50.59M+43.5%	-$76.86M-18.2%	-$85M-36.4%
Accumulated other comprehensive income (loss)	$479K-86.7%	$1.03M-80.7%	$2.81M-47.6%	$3.31M-60.2%	$3.61M-61.6%
Treasury stock	$53M+70.7%	$33.25M+58.0%	$32.64M+57.5%	$31.59M+57.6%	$31.04M+65.6%
Total stockholders' equity	$562.3M+34.3%	$540.72M+33.9%	$505.82M+24.6%	$436.76M-4.2%	$418.62M-7.4%
Total liabilities and stockholders' equity	$1.42B+10.0%	$1.44B+12.1%	$1.41B+9.4%	$1.34B+45.9%	$1.29B+41.3%
Available-for-Sale Debt Securities - Amortized Cost	$14.89M+176%	$9.13M+44.8%	$8.86M+6.8%	$5.72M—	$5.39M—
Current Equity Amortized Cost	$14.89M+176%	$9.13M+44.8%	$8.86M+6.8%	$5.72M—	$5.39M—
Derivative Assets - Fair Value	$1.51M-58.1%	$1.65M-66.4%	$2.23M-37.2%	$2.81M-61.8%	$3.61M-52.8%
Equity Securities (FV-NI) - Cost Basis	$14.89M+176%	$9.13M+44.8%	$8.86M+6.8%	$5.72M—	$5.39M—
Deferred Tax Assets and Other Non-Current Assets	$11.58M+12.2%	$13.71M+12.2%	$12.5M+9.0%	$8.25M-35.8%	$10.31M-24.0%
Equity Amortized Cost	$14.89M+176%	$9.13M+44.8%	$8.86M+6.8%	$5.72M—	$5.39M—
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	——	——	——	——
Finite Lived Intangible Assets - Gross	$936.17M+2.7%	$929.87M+4.0%	$929.79M+3.6%	$929.89M+87.2%	$911.2M+83.4%
Investments - Cost Basis	$14.89M+176%	$9.13M+44.8%	$8.86M+6.8%	$5.72M—	$5.39M—
Deferred tax assets	$66.56M-24.8%	$69.07M-18.8%	$71.4M+5.5%	$92.03M+2.8%	$88.49M+1.0%
Intangible assets — net	$467.16M-10.6%	$479.53M-8.8%	$499.82M-9.1%	$520.32M+219%	$522.7M+197%
Other intangible assets—net	$467.16M-13.2%	$479.53M-11.5%	$499.82M-12.3%	$520.32M+184%	$538.5M+175%
Other non-current assets	$11.58M+12.2%	$13.71M+12.2%	$12.5M+9.0%	$8.25M-35.8%	$10.31M-24.0%
Software and Technology Licenses, Net	$11.58M+12.2%	$13.71M+12.2%	$12.5M+9.0%	$8.25M-35.8%	$10.31M-24.0%
Accrued Manufacturing Costs	$16.09M-27.8%	$37.9M+0.5%	$33.22M+11.6%	$32.93M+104%	$22.3M+134%
Accrued Royalties (Current)	$33.93M+43.1%	$48.5M+114%	$51.25M+119%	$36.03M+77.0%	$23.71M+53.2%
Other Commercial Liabilities	$13.74M+14.2%	$16.97M+23.6%	$13.95M-21.7%	$14.76M+113%	$12.03M+61.9%
Accrued Government Rebates	$38.42M+69.7%	$43.15M+131%	$37.03M+246%	$32.87M+167%	$22.64M+138%
Accrued Liabilities, Current	$13.74M+14.2%	$16.97M+23.6%	$13.95M-21.7%	$14.76M+113%	$12.03M+61.9%
Compensation and benefits	$16.09M-27.8%	$37.9M+0.5%	$33.22M+11.6%	$32.93M+104%	$22.3M+134%
Income taxes payable - foreign	——	——	——	——	——
Returned Goods Reserve	$43.05M+1.4%	$49.5M+26.0%	$50.01M+34.9%	$48.68M+43.6%	$42.46M+29.3%
Contingent Consideration Liability (Non-Current)	$9.25M-46.9%	$9.61M-51.5%	$11.38M-43.6%	$18.09M+63.1%	$17.43M+56.1%
Total debt	$305.29M-3.5%	$320.36M-1.4%	$318.12M-0.6%	$314.7M+10.3%	$316.49M+10.9%
Convertible Preferred Stock Authorized Shares	1.7M0.0%	1.7M0.0%	1.7M0.0%	1.7M0.0%	1.7M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—	0—
Class C Special Stock Value	$0—	$0—	$0—	$0—	$0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$3K+50.0%	$3K+50.0%	$3K+50.0%	$2K0.0%	$2K0.0%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	$0—
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Cumulative Cost Basis	$14.89M+176%	$9.13M+44.8%	$8.86M+6.8%	$5.72M—	$5.39M—
Fair Value Measurement Disclosure	$8.57M-26.5%	$8.35M-23.1%	$7.97M-37.6%	$12.57M+5.4%	$11.66M+0.7%
Accrued licensor payment	$0—	$0—	$4.06M—	$11.43M—	——
Licensing Arrangements	$33.93M+43.1%	$48.5M+114%	$51.25M+119%	$36.03M+77.0%	$23.71M+53.2%
Business Combination, Contingent Consideration, Liability	$8.6M-26.5%	$8.3M-23.9%	$8M-37.5%	$12.6M—	$11.7M—
Convertible notes, net	$308.47M—	$307.93M—	$307.39M—	$306.86M—	——
Cost	$14.89M+176%	$9.13M+44.8%	$8.86M+6.8%	$5.72M—	$5.39M—
Current maturities of long-term debt	——	——	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$469.01M+20.7%	$450.35M+22.4%	$429.97M+23.8%	$409.57M+22.8%	$388.5M+21.2%
2028	——	——	——	——	——
2030	——	——	——	——	——
2031	——	——	——	——	——
Remainder of 2026	——	——	——	——	——
2027	——	——	——	——	——
2029	——	——	——	——	——
2032 and thereafter	——	——	——	——	——
Gross Carrying Amount	$936.17M+2.7%	$929.87M+4.0%	$929.79M+3.6%	$929.89M+87.2%	$911.2M+83.4%
Raw materials	$83.33M+37.0%	$84.11M+25.2%	$68.65M+2.1%	$63.85M+2.0%	$60.83M+10.4%
Royalty percentage	——	——	——	——	——
Established brand products	——	——	——	——	——
Number of European countries	——	——	——	——	——
Number of executives and founderes	——	——	——	——	——
Number of new products	——	——	——	——	——
Number of pharmaceutical manufacturing facilities	——	——	——	——	——
Product families	——	——	——	——	——
Number of products marketed	——	——	——	——	——
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$1.67M0.0%	$1.67M0.0%	$1.67M0.0%	$1.67M0.0%	$1.67M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—	$0—
Prepaid expenses	$22.09M-5.3%	$34.22M+90.4%	$18.55M+6.2%	$15.11M+7.9%	$23.33M+45.3%
Shares awarded upon vesting (in shares)	——	——	——	——	——
Stockholders' Equity Attributable to Parent and Temporary Equity	$562.3M+26.8%	$540.72M+26.2%	$505.82M+17.4%	$461.61M-4.0%	$443.47M-7.0%
Treasury stock, shares (in shares)	$881.49K+48.7%	$621.3K+44.6%	$613.97K+44.8%	$601.99K+45.9%	$592.96K+50.9%
Remainder of Fiscal Year 2024	——	——	——	——	——
Remainder of Fiscal Year 2025	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about ANI Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are ANI Pharmaceuticals's total assets?: ANI Pharmaceuticals (ANIP) holds $1.4B in total assets, up 10.0% year over year.
How much debt does ANI Pharmaceuticals have?: ANI Pharmaceuticals carries $305.3M in total debt against $562.3M of shareholders' equity, a debt-to-equity ratio of 0.54.
How much cash does ANI Pharmaceuticals have?: ANI Pharmaceuticals holds $311.2M in cash and equivalents.
Can ANI Pharmaceuticals cover its short-term obligations?: Its current ratio is 3.12 — current assets exceed current liabilities.
Where does ANI Pharmaceuticals's balance sheet data come from?: Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.